Ginkgetin aglycone treatment reduces oxidative stress and inflammation to protect against neuronal injury in stroke via activation of the PI3K/AKT/NF-κB/TLR4/Bcl-2 pathway (84). The gene discussed is AKT1; the disease is stroke disorder.